Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20899573 | 0.94 | LMNA (0.67) | SIRT6POLBMAPTLMNAALDH1A1 | |
| SCHEMBL28901607 | 0.86 | MEN1 (0.66) | SIRT6POLBMAPTLMNAALDH1A1 | |
| SCHEMBL15271381 | 0.86 | SIRT6 (0.81) | SIRT6POLBMAPTLMNAALDH1A1 | |
| SCHEMBL6151230 | 0.86 | SIRT6 (0.81) | SIRT6POLBMAPTLMNAALDH1A1 | |
| SCHEMBL18539466 | 0.83 | SIRT6 (0.46) | SIRT6POLBMAPTLMNAALDH1A1 | |
| SCHEMBL447471 | 0.81 | SIRT6 (1.00) | SIRT6POLBMAPTLMNAALDH1A1 | |
| SCHEMBL12240580 | 0.81 | SIRT6 (0.74) | SIRT6POLBMAPTLMNAALDH1A1 | |
| SCHEMBL7048817 | 0.80 | MAPT (0.85) | SIRT6POLBMAPTLMNAALDH1A1 | |
| SCHEMBL943807 | 0.80 | SIRT6 (0.62) | SIRT6POLBMAPTLMNAALDH1A1 | |
| SCHEMBL16654817 | 0.79 | MAPT (0.57) | SIRT6POLBMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-01-09 | — | — | US | disclosed |
| WO-2023092098-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences, S.R.L. (IT) | 2021-09-30 | — | — | US | disclosed |
| EP-3694509-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Nuvation Bio Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-05-07 | — | — | US | disclosed |
| US-7482354-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-7482354-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-08-09 | — | — | US | disclosed |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-08-09 | — | — | US | disclosed |
| EP-1636236-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004104007-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | SIRT6 1654/4885POLB 1522/4885MAPT 2476/4885 |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | SIRT6 1659/4885POLB 1584/4885MAPT 2491/4885 |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP4K2 | SIRT6 1659/4885POLB 1584/4885MAPT 2491/4885 |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | SIRT6 3520/4885POLB 159/4885MAPT 3393/4885 |
| US-20200115709-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | SIRT6 3520/4885POLB 159/4885MAPT 3393/4885 |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | SIRT6 1654/4885POLB 1522/4885MAPT 2476/4885 |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP3K19 | SIRT6 1498/4885POLB 1577/4885MAPT 1972/4885 |
| US-10344281-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | SIRT6 3520/4885POLB 159/4885MAPT 3393/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | SIRT6 3520/4885POLB 159/4885MAPT 3393/4885 |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | P2RX5, P2RX3, IL1B | SIRT6 1496/4885POLB 1559/4885MAPT 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.